Merck & Co. (MRK) Q4 2024 Annual Earnings
MRK·Reported February 4, 2025·Before market open
Merck & Co. reported Q4 2024 revenue of $15.6B, beat analyst consensus of $15.5B by $141.3M. Diluted EPS came in at $1.72, missed the $1.85 consensus by $0.13. Merck & Co. reports across 2 business segments, led by Pharmaceutical and Animal Health.
Revenue
$15.6Bbeat by $141.3M
Consensus: $15.5BDiluted EPS
$1.72missed by $0.13
Consensus: $1.85
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Merck & Co.'s Q4 2024 earnings report.
Merck & Co. (MRK) reported Q4 2024 earnings on February 4, 2025 before market open.
Merck & Co. reported revenue of $15.6B and diluted EPS of $1.72 for Q4 2024.
Revenue beat the consensus estimate of $15.5B by $141.3M. EPS missed the consensus estimate of $1.85 by $0.13.
You can read the 10-K periodic report (0001628280-25-007732) directly on SEC EDGAR. The filing index links above go to sec.gov.